Wall Street analyst estimates for MetaVia Inc. (MTVA): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH).
Valuation Ratios
| Price / Book | 1.34 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | $67000 | $72000 | $28000 | $7000 | $24000 | $19000 |
| Gross Profit | 0 | 0 | 0 | 0 | -$67000 | -$72000 | -$28000 | -$7000 | -$24000 | -$19000 |
| Research & Development | $8.7M | $22.7M | $13.9M | $17.5M | $21.9M | $6.5M | $2.8M | $9.2M | $21.5M | $6.8M |
| Selling, General & Admin | $6.0M | $10.4M | $1.6M | $2.7M | $7.8M | $8.8M | $8.6M | $6.7M | $7.3M | $6.9M |
| Operating Expenses | $14.7M | $33.1M | $15.5M | $20.2M | $29.7M | $15.3M | $19.6M | $15.9M | $28.8M | $13.7M |
| Operating Income | -$14.7M | -$33.1M | -$15.5M | -$20.2M | -$29.7M | -$15.3M | -$19.6M | -$15.9M | -$28.8M | -$13.7M |
| EBITDA | -$14.7M | -$33.1M | -$15.5M | -$20.2M | -$29.7M | -$15.2M | -$11.8M | -$12.5M | -$27.6M | -$13.0M |
| Interest Expense | 0 | $286000 | $40000 | $22000 | 0 | 0 | $2.2M | 0 | 0 | 0 |
| Pre-tax Income | -$14.6M | -$33.4M | -$15.5M | -$21.3M | -$29.7M | -$15.3M | -$14.0M | -$12.5M | -$27.6M | -$13.0M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$14.6M | -$33.4M | -$15.5M | -$21.3M | -$29.7M | -$15.3M | -$14.0M | -$12.5M | -$27.6M | -$13.0M |
| EPS | $-106454.37 | $-213180.00 | $-112860.00 | $-10771.20 | $-4831.20 | $-1742.40 | $-477.84 | $-27.06 | $-39.16 | $-7.35 |
| EPS (Diluted) | $-106454.37 | $-213180.00 | $-112860.00 | $-10771.20 | $-4831.20 | $-1742.40 | $-477.84 | $-27.06 | $-39.16 | $-7.35 |
| Shares Outstanding (Diluted) | $140 | $157 | $209 | $1979 | $6143 | $8767 | $29246 | $461009 | $705193 | $1.8M |
Price
| Price | $1.54 |
| Market Cap | $3M |
| Exchange | NASDAQ |
| Country | US |
Related companies: CASI · CLGN · CLSD · ENLV · KLTO · LSTA · NCNA
Explore sector: Healthcare · Biotechnology
More sections of MTVA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks